Cuprina Holdings (Cayman) Limited Class A (CUPR) AI Stock Analysis

Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company focused on developing and commercializing products for the management of chronic wounds. Headquartered in Singapore and founded in 2019, it operates as a subsidiary of Cuprina Holding Pte. Ltd. The company manufactures and distributes medical grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand name, serving as a biological debridement tool. Additionally, Cuprina is developing wound treatment products using medical leeches, as well as collagen dressings such as sponges, particles, and hydrogels derived from bullfrog collagen sourced from abattoir waste streams.

Between FY2021 and FY2025, Cuprina experienced a 4-year revenue compound annual growth rate of -3.9%. Annual revenue moved from $58,504 in FY2021 to $100,773 in FY2023, before declining to $48,321 in FY2024 and rebounding 3.3% to $49,894 in FY2025. Gross margin contracted from 39.4% in FY2021 to -1.3% in FY2025. The company's operating margin worsened from -944.8% in FY2021 to -9154.6% in FY2025, expanding its annual net loss from -$519,686 to -$4.7M. In the latest quarter ended March 31, 2026, quarterly revenue grew 267.4% year-over-year, while trailing twelve-month revenue totaled $49,894 with an operating margin of -10568.4%.

As of March 31, 2026, Cuprina held $3.1M in cash and short-term investments against total debt of $482,719, resulting in net cash of $2.6M. Shareholders' equity was $5.1M and total assets stood at $8.5M, supporting a current ratio of 2.35 and a debt-to-equity ratio of 0.10. For FY2025, operating cash flow was -$9.1M, and free cash flow was -$9.2M after capital expenditures of $58,229.

Cuprina trades at a price-to-sales ratio of 266.7x and an enterprise-value-to-revenue multiple of 287.6x, compared to the median of its US-listed Healthcare peers of 4.1x. Its price-to-book ratio is 3.4x, supported by a market capitalization of $13.3M and an enterprise value of $11.2M. Over the past year, CUPR shares fell 74.5%, significantly underperforming the S&P 500 return of 16.8%. The stock closed at $1.90 on October 16, 2026, positioned 38.9% below its 200-day average and down 40.6% year-to-date.

Cuprina Holdings has no analyst buy, hold, or sell ratings, price targets, or forward revenue estimates available in the provided data. The company has no reported earnings track record or scheduled next earnings date. With a market capitalization of $13.3M and trailing twelve-month diluted earnings per share of -$1.40, Wall Street research coverage on the stock remains absent, leaving investors to assess performance based solely on reported financial results.

This page is an AI-written research summary of Cuprina Holdings (Cayman) Limited Class A (CUPR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CUPR income statement, CUPR balance sheet, CUPR key metrics, CUPR chart. See the CUPR stock overview for the latest quote and news.